Molecular Subtype
Primary CD30-Positive T-Cell Lymphoproliferative Disorder
CI-CAN-00006485Explore in graph →
HematologicNon-malignant5 active trials
- NCIt
- C202952
Loading cancer entity…
Molecular Subtype
CI-CAN-00006485Explore in graph →
Clinical trials
13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07717580 | Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)(BV-LISA-CTCL) | not yet recruiting | Phase 2 | 46 | Peking University First HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2026source: clinicaltrials